Welcome to ClinLife!
ClinLife is the patient portal for clinical trials.
We provide the public with free access to clinical trials and help individuals volunteer for the clinical trial of their choice. We publish information about ongoing trials, and we keep you up-to-date on medical conditions, on treatments and on current research news.
ClinLife is a network of trial volunteers, patients, physicians, clinical trial doctors, outreach programs, and many other individuals all involved in the clinical trial community. In other words, we are the bridge between trial volunteers and local, regional and national clinical trial centres.
If you are looking for specific trials in your area, please use the "Search for Trials" box located above to browse our database for current trials. To find some general information about clinical research trials, please read our short introduction to clinical trials.
We thank you for visiting our patient portal and for allowing us to connect you with the clinical trial community. We welcome any questions or comments you may have, so please feel free to contact us at anytime.
Please note that our services are entirely free of charge. Your registration with ClinLife does not oblige you to participate in any of the trials listed in our portal.
The FOURIER Study
The purpose of the FOURIER study is to find out if an investigational medication may reduce the risk of cardiovascular events.
Diabetic peripheral neuropathy research study
Do you have diabetes mellitus and chronic pain in your extremities caused by nerve damage? You may qualify for a research study if you:
• are between the ages of 18 and 80 years old
• have pain for more than 3 months in your feet, hands and/or limbs with symptoms such as numbness, tingling, shooting or electric-shock pain, and/or sensitivity of the skin towards touch, warm or cold temperatures
• are currently taking pain medication for at least 1 month and you are not satisfied with the treatment
There are currently no results for your selection. Please check back later.